| 000 | 00789 a2200229 4500 | ||
|---|---|---|---|
| 005 | 20250513171324.0 | ||
| 264 | 0 | _c19990622 | |
| 008 | 199906s 0 0 eng d | ||
| 022 | _a0143-3636 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAllen, B J | |
| 245 | 0 | 0 |
_aCan alpha-immunotherapy succeed where other systemic modalities have failed? _h[electronic resource] |
| 260 |
_bNuclear medicine communications _cMar 1999 |
||
| 300 |
_a205-7 p. _bdigital |
||
| 500 | _aPublication Type: Editorial | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotherapy _xmethods |
| 650 | 0 | 4 | _aImmunotoxins |
| 650 | 0 | 4 |
_aNeoplasm Metastasis _xprevention & control |
| 773 | 0 |
_tNuclear medicine communications _gvol. 20 _gno. 3 _gp. 205-7 |
|
| 999 |
_c10052780 _d10052780 |
||